Med BioGene signs letter of intent with the Ontario Institute for Cancer Research

By Elaine Rigoli

Tampa, Fla., June 23 - Med BioGene, Inc. has signed a letter of intent with the Ontario Institute for Cancer Research in which the Ontario Tumour Bank, an initiative of the institute, will provide to Med BioGene tumor tissue samples of confirmed lymphoma patients.

Such samples may also include normal adjacent tissue and/or buffy coat samples, according to a news release.

"Our relationship with the Ontario Institute for Cancer Research and receipt of the tissue samples from the Ontario Tumour Bank will be of great importance as Med BioGene continues to develop and test its diagnostic lymphoma bioarray. We are looking forward to receiving the approval of the Tissue Ethics Committee and aggressively moving forward with the development of our product," chief executive officer Erinn Broshko said in the release.

In 2004, Med BioGene filed a U.S. patent application for its hematological cancer profiling system relating to its diagnostic lymphoma bioarray and diagnostic leukemia bioarray.

Med BioGene is a Vancouver, B.C.-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.